Equities Analysts Set Expectations for Indaptus Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Indaptus Therapeutics in a research note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Trading Down 4.7 %

Shares of Indaptus Therapeutics stock opened at $2.66 on Tuesday. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The stock’s fifty day moving average price is $2.13 and its 200-day moving average price is $2.10. The firm has a market cap of $22.72 million, a P/E ratio of -1.45 and a beta of 1.28.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07.

Institutional Investors Weigh In On Indaptus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Indaptus Therapeutics by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after purchasing an additional 5,517 shares during the period. Citadel Advisors LLC purchased a new position in Indaptus Therapeutics during the fourth quarter valued at approximately $29,000. Renaissance Technologies LLC purchased a new position in Indaptus Therapeutics during the second quarter valued at approximately $51,000. State Street Corp purchased a new position in Indaptus Therapeutics during the first quarter valued at approximately $78,000. Finally, Northern Trust Corp purchased a new position in Indaptus Therapeutics during the first quarter valued at approximately $41,000. Institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.